Monday, June 20, 2011

Ultragenyx Raises $45M

Novato-based Ultragenx Pharmaceuticals said today that it has raised $45M in a Series A funding round. The round was led by TPG Biotech and Fidelity Biosciences, and also included HealthCap and Pappas Ventures. According to the firm, the funding will go towards advancing multiple rare disease product programs. Ultragenx is headed by Dr. Emil D. Kakkis, the former Chief Medical Officer of BioMarin Pharmaceuticals. The company's first compound is aimed at treating Hereditary Inclusion Body Myopathy (HIBM). More information »